Presenting Pivotal Phase 3 Sickle Cell Data at EHA 2026- Agios Pharmaceuticals
Agios Pharmaceuticals shared a post on LinkedIn:
“Agios News: Today, during the Plenary Abstracts Session at EHA 2026, we presented detailed results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.
This oral presentation included new transfusion burden and hemoglobin responder analyses that reinforce the strong anti-hemolytic profile of our first-in-class PK activator.
Read the results.”
Mohamed A., Franchise Director, Blood Disorders, Rare Disease GCC at NewBridge Pharmaceuticals, shared this post on LinkedIn:
“Results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Nov 3, 2026, 22:00Ravi C Dara: What’s New in ASFA’s 10th Edition – Practical Updates for the Apheresis Clinician
-
Nov 3, 2026, 21:46Cedric Hermans: Treatment Differentiators for Shared Decision-Making in Haemophilia in 2026
-
Nov 3, 2026, 21:38Arwa Z. Al-Riyami: AI Opportunities and Future Directions in Transfusion Medicine
-
Nov 3, 2026, 21:11Yazan Abou-Ismail: Presenting at American College of Emergency Physicians and MWTCC in the Same Week
-
Nov 3, 2026, 21:05Anirban Sen Gupta: Escalating-Dose Lyophilized SynthoPlate for Emergency Trauma Mitigation
-
Nov 3, 2026, 20:50Mostafa Faisal Mohammed Saleh: Targeting Plasma Cells to Control Persistent ADAMTS13 Autoantibodies in iTTP
-
Nov 3, 2026, 16:57Ahmed Alotaibi: Which Macrophage Receptor ‘eats’ anti-E and Anti-K Coated RBCs?
-
Nov 3, 2026, 16:53Jan Sloves: Key Factors for Achieving Durable Patency in Advanced Venous Stenting
-
Nov 3, 2026, 16:45Nina Weber: Review on Kidney Injury After Stem Cell Transplantation